CRISPR Therapeutics (CRSP) counsel sells 2,800 shares to cover RSU taxes

Rhea-AI Filing Summary

CRISPR Therapeutics AG General Counsel and Secretary James R. Kasinger reported an RSU vesting and related share sale. On March 10, 2026, he acquired 5,500 Common Shares at $0.00 per share through the exercise of Restricted Stock Units, reflecting part of a 22,000-share award granted on March 10, 2023.

On March 11, 2026, he sold 2,800 Common Shares at an average price of $52.80 per share. A footnote states these shares were sold to cover tax withholding obligations under the company’s RSU Settlement Policy and were not a discretionary trade. After these transactions, he directly owned 87,815 Common Shares.

Insider Trade Summary

Net Seller: 2,800 shares ($147,840)

Net Sell 3 txns

Insider KASINGER JAMES R.

Role General Counsel and Secretary

Sold 2,800 shs ($148K)

Type	Security	Shares	Price	Value
Sale	Common Shares	2,800	$52.80	$148K
Exercise	Restricted Stock Units	5,500	$0.00	--
Exercise	Common Shares	5,500	$0.00	--

Holdings After Transaction: Common Shares — 87,815 shares (Direct); Restricted Stock Units — 5,500 shares (Direct)

Footnotes (1)

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KASINGER JAMES R.

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/10/2026		M(1)		5,500	A	(2)	90,615	D
Common Shares	03/11/2026		S		2,800(3)	D	$52.8	87,815	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/10/2026		M(1)			5,500	(4)	(4)	Common Shares	5,500	(2)	5,500	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

4. This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.

	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CRISPR Therapeutics (CRSP) report for James R. Kasinger?

James R. Kasinger reported an RSU vesting and a related share sale. He acquired 5,500 Common Shares via Restricted Stock Units on March 10, 2026, then sold 2,800 Common Shares on March 11, 2026, primarily to cover tax withholding obligations.

How many CRISPR Therapeutics (CRSP) shares did James R. Kasinger sell and at what price?

Kasinger sold 2,800 CRISPR Therapeutics Common Shares at $52.80 per share. The filing explains this transaction was executed to satisfy tax withholding obligations tied to vesting Restricted Stock Units, under the company’s RSU Settlement Policy, rather than as a discretionary open-market sale.

Why were CRISPR Therapeutics (CRSP) shares sold in James R. Kasinger’s Form 4 filing?

The shares were sold to cover tax withholding from RSU vesting. A footnote states 2,800 shares were required to fund the tax obligation related to vested Restricted Stock Units and that this sale was mandated by company policy, not initiated at the insider’s discretion.

How many CRISPR Therapeutics (CRSP) shares does James R. Kasinger hold after these transactions?

After the reported transactions, Kasinger directly holds 87,815 Common Shares. This figure reflects his position following the 5,500-share RSU conversion into Common Shares and the subsequent 2,800-share sale to satisfy tax withholding requirements.

What are the key details of James R. Kasinger’s RSU award at CRISPR Therapeutics (CRSP)?

The RSU award was granted on March 10, 2023 for 22,000 shares. Vesting occurs in four equal annual installments on March 10 of 2024, 2025, 2026, and 2027, with each vested portion representing a contingent right to receive one Common Share per unit.

Are James R. Kasinger’s CRISPR Therapeutics (CRSP) transactions considered routine or discretionary?

The Form 4 indicates the share sale was routine for tax withholding. Footnotes specify the 2,800-share sale was mandated by the company’s RSU Settlement Policy to cover tax obligations, rather than a discretionary trading decision in the open market.